^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Progesterone receptor agonist

    Related drugs:
    2d
    Podocalyxin may be down-regulated by progesterone in high grade serous ovarian cancer spheroids to increase responsiveness to carboplatin and NK cells. (PubMed, BMC Cancer)
    These findings suggest that further studies should explore the utility of progesterone-mediated down-regulation of PODXL in HGSC cancer to increase responsiveness to chemotherapy and NK cells.
    Journal
    |
    PODXL (Podocalyxin)
    |
    carboplatin
    2d
    Multifaceted Benefits of Auricular Point Sticking for IVF Patients: Psychological Well-being, Sleep, and Treatment Outcomes (clinicaltrials.gov)
    P=N/A, N=178, Enrolling by invitation, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University | Trial completion date: Dec 2026 --> Mar 2027 | Initiation date: Aug 2025 --> Feb 2026 | Trial primary completion date: Oct 2026 --> Jan 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    4d
    A Multicellular Coordinated Network Driving Lymphovascular Space Invasion in Endometrioid Endometrial Carcinoma. (PubMed, Cell Prolif)
    LVSI+ EECs exhibited marked epithelial reprogramming, transitioning from differentiated ciliated epithelium to hyperproliferative and metabolically remodelled phenotypes, and contained TC4, a metastatic epithelial subset characterized by hypoxia, partial epithelial-mesenchymal transition, immunosuppression, and progesterone resistance...Using spatial multiplex immunofluorescence, we confirmed hypoxic tumour epithelial cells at the invasive front coexisting with an immunosuppressive microenvironment, and revealed spatial colocalization of PD-L1+ tumour cells, PD-L1+ macrophages, and PD-1+ T cells within LVSI thrombi. Our comprehensive study provides deeper insights into LVSI as an actively coordinated multicellular process, potentially improving LVSI risk prediction, supporting treatment decision-making, and informing new therapies targeting the tumour microenvironment.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • SPP1 (Secreted Phosphoprotein 1) • MMP9 (Matrix metallopeptidase 9) • LGALS9 (Galectin 9) • SOX4 (SRY-Box Transcription Factor 4)
    5d
    CineP4: Early Luteal Phase Progesterone Kinetics After hCG-Induced Ovulation in Modified Natural Cycle (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, University Hospital, Montpellier | Not yet recruiting --> Recruiting
    Enrollment open
    9d
    A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the Blood (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Boehringer Ingelheim
    New P1 trial
    |
    midazolam hydrochloride
    10d
    MP4 MPS: Progesterone and Muscle Protein Synthesis in Premenopausal Women (MP4-MPS) (clinicaltrials.gov)
    P1, N=20, Completed, McMaster University | Not yet recruiting --> Completed | Trial completion date: Dec 2025 --> May 2026 | Initiation date: Sep 2025 --> Jan 2026 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion • Trial completion date • Trial initiation date • Trial primary completion date
    10d
    Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101 (clinicaltrials.gov)
    P2, N=135, Recruiting, MetaFines | Not yet recruiting --> Recruiting | Trial completion date: Jul 2027 --> Jun 2028 | Initiation date: Sep 2025 --> May 2026 | Trial primary completion date: Mar 2026 --> Apr 2028
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    megestrol
    11d
    Fetal Growth Restriction a Case Control Study (clinicaltrials.gov)
    P=N/A, N=58, Recruiting, National University of Malaysia | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HMOX1 (Heme Oxygenase 1)
    15d
    SCD CURE: Effects of the Contraceptive Implant in Women With Sickle Cell Disease (clinicaltrials.gov)
    P4, N=22, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Mar 2027 | Trial primary completion date: Jun 2026 --> Mar 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    15d
    Endometrial BCL6 Expression and Reproductive Outcomes in Infertile Women: A Systematic Review. (PubMed, Diagnostics (Basel))
    Background/Objectives: Endometrial B-cell lymphoma 6 (BCL6) overexpression has been proposed as a marker of progesterone resistance, occult endometriosis, and endometrial dysfunction in infertile women...Its apparent prognostic and clinical utility varies across patient populations and reproductive settings. Larger prospective comparative studies with harmonized biopsy protocols, standardized outcome reporting, and independent external validation are needed to clarify the role of BCL6 in reproductive medicine.
    Review • Journal
    |
    BCL6 (B-cell CLL/lymphoma 6)
    15d
    The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial (clinicaltrials.gov)
    P3, N=110, Recruiting, Main Line Health | Trial completion date: Aug 2026 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Orgovyx (relugolix)
    15d
    Intrauterine Stent Placement Following Hysteroscopic Septum Resection (clinicaltrials.gov)
    P=N/A, N=320, Recruiting, Weill Medical College of Cornell University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    medroxyprogesterone